Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
The U.S. Government Should Buy Gilead For $156 Billion To Save Money On Hepatitis C

The U.S. government could cure most Americans suffering from hepatitis C infections if it simply bought drug maker Gilead Sciences on the stock market rather than purchasing its products in the drug market.

Published
17 January 2017
From
Forbes
Tenofovir alafenamide approved for hepatitis B in Europe

The European Commission this week granted marketing authorisation for tenofovir alafenamide, to be sold under the brand name Vemlidy, for the treatment of chronic hepatitis

Published
17 January 2017
By
Liz Highleyman
European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection

Vemlidy® is the First New Treatment for Chronic Hepatitis B Infection to be Approved in the European Union in Nearly a Decade

Published
12 January 2017
From
Gilead press release
Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) for Chronic Hepatitis C Achieved High SVR12 Rates in Genotype 1 Japanese Patients

99 percent (n=105/106) of genotype 1 (GT1) chronic HCV-infected Japanese patients without cirrhosis achieved SVR[12] with 8 weeks of G/P.

Published
09 January 2017
From
AbbVIe press release
People with HIV/HCV co-infection at increased risk of kidney disease and bone disorders

Hepatitis C virus (HCV) infection in people with HIV co-infection is associated with an increased risk of liver disease and liver-related death and also several important non-liver related

Published
02 January 2017
By
Michael Carter
Access to highly effective hepatitis C treatment in Portugal: A Community Perspective

This document presents a case study of community engagement for highly effective hepatitis C treatment, led by the Grupo de Ativistas em Tratamentos. It demonstrates the process of price and reimbursement negotiations in Portugal and lessons learned in advocacy for universal (or as close as possible) access to these and other life-saving drugs.

Published
19 December 2016
From
EATG
Gilead’s Patent Loss to Merck Started With a Broken Friendship

Jury may have been swayed by ‘story of betrayal,’ lawyers say. Gilead will use law, not emotion, to seek to overturn verdict.

Published
19 December 2016
From
Bloomberg
Hepatitis C patients 'go abroad for drugs'

Charities and liver specialists are warning that people with Hepatitis C are buying medications from India, to avoid long waits on the NHS. Radio 4's You & Yours has seen confidential documents, which suggest the cost to the NHS of some medications has dropped by nearly three-quarters, but experts say that NHS England still has not increased the number of patients it will treat.

Published
19 December 2016
From
BBC Radio 4 (audio)
Merck wins $2.54 billion in hepatitis C drug trial against Gilead

Merck & Co on Thursday was awarded $2.54 billion in royalties by a federal jury in a patent lawsuit against Gilead Sciences Inc over Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni.

Published
16 December 2016
From
Reuters
Almost half of MSM with HIV/HCV co-infection have HCV in their rectal fluid

Almost half of HIV-positive men who have sex with men (MSM) who have co-infection with hepatitis C virus (HCV) have detectable HCV in their rectal fluid,

Published
08 December 2016
By
Michael Carter

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.